VOL NO REGD NO DA 1589

Monday, November 21, 2005

HEADLINE

POLITICS & POLICIES

METRO & COUNTRY

VIEWS & REVIEWS

EDITORIAL

LETTER TO EDITOR

COMPANY & FINANCE

BUSINESS & FINANCE

TRADE/ECONOMY

LEISURE & ENTERTAINMENT

MARKET & COMMODITIES

SPORTS

WORLD

 

FE Specials

FE Education

Urban Property

Monthly Roundup

Saturday Feature

Asia/South Asia

 

Feature

13th SAARC SUMMIT DHAKA-2005

WOMEN & ECONOMY

57th Republic Day of India

US TRADE SHOW

 

 

 

Archive

Site Search

 

HOME

MARKET & COMMODITIES
 
Aristopharma starts marketing Arictin tablet
FE Report
11/21/2005
 

          Aristopharma has started marketing Arictin tablet consisting of Cyproheptadine 4mg.
It is being manufactured in Bangladesh for the first time. Cyproheptadine is an antihistamine and is highly effective in the treatment of sneezing, cough, urticaria and other allergic manifestations.
But apart from its anti-allergic actions it is also used as an appetite stimulant.
There are many children who do not like to eat which causes major a problem for their parents. Apart from children many young boys or girls or even adults suffer from loss of appetite, resulting in poor health. It creates a psychological stress upon them. In case of girls poor health sometimes causes a social problem as well.
Arictin can help these groups of people. It antagonises the action of serotonin in the appetite centre of our brain. As a result, appetite increases and the patient takes more food. When someone takes more food, he becomes healthy naturally. Thus Arictin makes people healthy in a physiological way. It is suitable for adults as well as children above two years of age.

 

 
  More Headline
Govt to bring new areas under tea cultivation to raise production
OPEC won't consider to change output
China, US to work towards more-flexible yuan: Bush
Asian currencies fall against dollar
Aristopharma starts marketing Arictin tablet
Diouf re-elected for 3rd term as FAO chief
Benchmark holds annual business meet
EU hits gridlock on banana tariff
 

Print this page | Mail this page | Save this page | Make this page my home page

About us  |  Contact us  |  Editor's panel  |  Career opportunity | Web Mail

 

 

 

 

Copy right @ financialexpress.com